Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220070
Ahmet Cem Esmer, Deniz Tazeoglu, Ahmet Dag
{"title":"Pseudoangiomatous stromal hyperplasia of the breast: Clinical evaluation.","authors":"Ahmet Cem Esmer,&nbsp;Deniz Tazeoglu,&nbsp;Ahmet Dag","doi":"10.3233/BD-220070","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.</p><p><strong>Methods: </strong>The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.</p><p><strong>Results: </strong>17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.</p><p><strong>Conclusion: </strong>For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pseudoangiomatous stromal hyperplasia is a rare benign breast stromal proliferative lesion of the breast. Clinical presentation ranges from rapidly growing mass to incidental identification in routine screening. This difference in manifestation and its rarity makes it difficult to be a standard treatment protocol. Therefore, we aimed to share our clinical experience in Pseudoangiomatous stromal hyperplasia.

Methods: The files of patients who underwent core biopsy or surgical excision due to a breast mass and resulted in pseudoangiomatous stromal hyperplasia between January 2013 and December 2021 were included in the study.

Results: 17 patients with a median age of 37 (22-68) were found Pseudoangiomatous stromal hyperplasia confirmed by surgical excision or core biopsy. Chosen treatment option was observation in 8 patients (47.1%), while surgical excision was used in 9 (52.9%) patients. The mean follow-up period was 55.24 ± 26.72 (13-102) months. None of the patients observed the Malignant transformation during the follow-up period.

Conclusion: For Pseudoangiomatous Stromal Hyperplasia of the breast, surgical excision with clean margins or close follow-up after diagnosis confirmation by tissue biopsy is sufficient. Pseudoangiomatous Stromal Hyperplasia is not a risk factor for developing breast cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺假性血管瘤间质增生:临床评价。
背景:假性血管瘤间质增生是一种罕见的乳腺良性间质增生性病变。临床表现从快速增长的肿块到在常规筛查中偶然发现。这种表现上的差异及其罕见性使其难以成为标准的治疗方案。因此,我们希望在此分享我们治疗假性血管瘤间质增生的临床经验。方法:纳入2013年1月至2021年12月期间因乳腺肿块接受核心活检或手术切除并导致假性血管瘤间质增生的患者档案。结果:17例患者中位年龄为37岁(22-68岁),经手术切除或核心活检证实为假性血管瘤间质增生。选择的治疗方案为观察8例(47.1%),手术切除9例(52.9%)。平均随访时间55.24±26.72(13-102)个月。随访期间未见恶性转化。结论:对于乳腺假性血管瘤性间质增生,经组织活检确认诊断后,行边缘清洁的手术切除或密切随访即可。假性血管瘤间质增生不是发生乳腺癌的危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast disease
Breast disease Medicine-Oncology
CiteScore
1.80
自引率
0.00%
发文量
59
期刊介绍: The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.
期刊最新文献
Sentinel node in breast cancer as an indicator of quality in medical care: Evaluation of statistics in Colombia. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer. Clinicopathological analysis of 38 male patients diagnosed with breast cancer. Impact of the COVID-19 pandemic on breast cancer pathological stage at diagnosis in Tunisian patients. Use of axillary ultrasound to guide breast cancer management in the genomic assay era.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1